Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Average Rating of "Hold" by Analysts

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) has earned an average rating of "Hold" from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $42.67.

Separately, Mizuho upped their price target on shares of Cerevel Therapeutics from $25.00 to $45.00 and gave the company a "neutral" rating in a research report on Friday, February 16th.

Insider Activity at Cerevel Therapeutics

In related news, Director N Anthony Coles sold 2,506 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $41.54, for a total transaction of $104,099.24. Following the completion of the sale, the director now owns 15,638 shares of the company's stock, valued at $649,602.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Cerevel Therapeutics news, Director N Anthony Coles sold 2,506 shares of the firm's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $41.54, for a total value of $104,099.24. Following the completion of the sale, the director now directly owns 15,638 shares in the company, valued at $649,602.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John Renger sold 2,161 shares of Cerevel Therapeutics stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $41.54, for a total transaction of $89,767.94. Following the completion of the sale, the insider now directly owns 6,370 shares of the company's stock, valued at $264,609.80. The disclosure for this sale can be found here. Insiders have sold a total of 104,667 shares of company stock worth $4,302,367 over the last quarter. Company insiders own 5.10% of the company's stock.

Institutional Trading of Cerevel Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CERE. Principal Financial Group Inc. increased its holdings in Cerevel Therapeutics by 1.6% during the 4th quarter. Principal Financial Group Inc. now owns 27,117 shares of the biotechnology company's stock worth $1,150,000 after purchasing an additional 430 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in Cerevel Therapeutics by 7.6% during the 3rd quarter. E Fund Management Co. Ltd. now owns 10,223 shares of the biotechnology company's stock worth $223,000 after acquiring an additional 722 shares during the last quarter. Amalgamated Bank grew its stake in shares of Cerevel Therapeutics by 8.8% in the 4th quarter. Amalgamated Bank now owns 10,027 shares of the biotechnology company's stock worth $425,000 after acquiring an additional 809 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Cerevel Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 17,818 shares of the biotechnology company's stock valued at $389,000 after purchasing an additional 818 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of Cerevel Therapeutics by 0.9% during the third quarter. Alps Advisors Inc. now owns 116,263 shares of the biotechnology company's stock valued at $2,538,000 after purchasing an additional 984 shares in the last quarter. Institutional investors own 87.73% of the company's stock.

Cerevel Therapeutics Trading Down 0.1 %

Shares of CERE stock traded down $0.04 during mid-day trading on Friday, reaching $42.55. 912,342 shares of the stock traded hands, compared to its average volume of 1,072,801. The stock's fifty day simple moving average is $41.99 and its two-hundred day simple moving average is $37.66. The company has a market cap of $7.73 billion, a price-to-earnings ratio of -17.02 and a beta of 1.46. Cerevel Therapeutics has a 1-year low of $19.59 and a 1-year high of $43.59. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.50.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.